Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 3-Hydroxybutyric Acid, (+/-)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL1881926 | 0.89 | SLC22A6 (0.56) | SLC22A6SMN1; SMN2MAPTGABRR1LMNA | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL2731 | 0.89 | — | — | |
| (R)-3-Hydroxybutanoate SCHEMBL336331 | 0.89 | — | — | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL1897117 | 0.89 | SLC22A6 (0.56) | SLC22A6SMN1; SMN2MAPTGABRR1LMNA | |
| (R)-3-Hydroxybutanoate SCHEMBL1533862 | 0.89 | SLC22A6 (0.56) | SLC22A6SMN1; SMN2MAPTGABRR1LMNA | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL28197574 | 0.89 | SLC22A6 (0.56) | SLC22A6SMN1; SMN2MAPTGABRR1LMNA | |
| (R)-3-Hydroxybutanoate SCHEMBL60959 | 0.89 | — | — | |
| (R)-3-Hydroxybutanoate SCHEMBL29903959 | 0.89 | — | — | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL2749471 | 0.86 | — | — | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL2342260 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110049760-B | Composition for treating inflammatory diseases, application thereof and probiotic composition | 链生物技术有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-10987325-B2 | Compositions and uses thereof for treating inflammatory diseases and probiotic compositions | CHAIN BIOTECHNOLOGY LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| EP-3515429-B1 | COMPOSITIONS COMPRISING GENETICALLY ENGINEERED ANAEROBIC BACTERIA WHICH PRODUCE (R)-3-HYDROXYBUTYRATE AND USES THEREOF FOR TREATING INFLAMMATORY DISEASES | CHAIN BIOTECHNOLOGY LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-20210023030-A1 | PHARMACEUTICAL COMPOSITIONS | CHAIN BIOTECHNOLOGY LIMITED (GB) | 2021-01-28 | — | — | US | disclosed |
| EP-3768252-A1 | PHARMACEUTICAL COMPOSITIONS | Chain Biotechnology Limited (GB) | 2021-01-27 | — | — | EP | disclosed |
| US-20200030266-A1 | COMPOSITIONS AND USES THEREOF FOR TREATING INFLAMMATORY DISEASES AND PROBIOTIC COMPOSITIONS | CHAIN BIOTECHNOLOGY LIMITED (GB) | 2020-01-30 | — | — | US | disclosed |
| WO-2019180441-A1 | PHARMACEUTICAL COMPOSITIONS | CHAIN BIOTECHNOLOGY LIMITED (GB) | 2019-09-26 | — | — | WO | disclosed |
| US-20190112621-A1 | METHOD AND MICROBES FOR THE PRODUCTION OF CHIRAL COMPOUNDS | CHAIN BIOTECHNOLOGY LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| EP-1792616-B1 | Composition comprising an HMG-CoA inhibitor and a nicotinic acid compound for treating hyperlipidemia | ABBOTT RESPIRATORY LLC (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-1792616-A1 | Composition comprising an HMG-CoA inhibitor and a nicotinic acid compound for treating hyperlipidemia | Kos Life Sciences, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1743630-A2 | Pharmaceutical combination | KOS PHARMACEUTICALS, INC. (US) | 2007-01-17 | — | — | EP | disclosed |